By Phil Wahba
NEW YORK, Oct 8 (Reuters) - Two new stocks debuted on U.S. exchanges on Thursday following their initial public offerings, with one barely rising and the other plunging.
Mistras Group Inc, which evaluates the structural integrity of public and private infrastructure, closed the day up 0.64 percent, or 8 cents, at $12.58 on the New York Stock Exchange in its first session after an IPO that priced below expectations.
Shares of Biotech company Omeros Corp
markets and sells a treatment for pain reliever-induced poisoning as well as a laxative.
Mistras sold 8.7 million shares in the IPO and raised $108.75 million. Of those, 2 million were sold by existing shareholders, including executives and private equity funds affiliated with Altus Capital Partners Inc.
The company, whose clients include Pfizer Inc and Exxon Mobil Corp, saw revenue rise 37.3 percent to $209.1 million in fiscal 2009, with net income of $5.5 million.
(Reporting by Phil Wahba, editing by Gerald E. McCormick, Tim Dobbyn, Leslie Gevirtz) Keywords: IPOS/DEBUTS (phil.wahba@thomsonreuters.com; +1 646 223 6128; Reuters Messaging: phil.wahba.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
NEW YORK, Oct 8 (Reuters) - Two new stocks debuted on U.S. exchanges on Thursday following their initial public offerings, with one barely rising and the other plunging.
Mistras Group Inc, which evaluates the structural integrity of public and private infrastructure, closed the day up 0.64 percent, or 8 cents, at $12.58 on the New York Stock Exchange in its first session after an IPO that priced below expectations.
Shares of Biotech company Omeros Corp
markets and sells a treatment for pain reliever-induced poisoning as well as a laxative.
Mistras sold 8.7 million shares in the IPO and raised $108.75 million. Of those, 2 million were sold by existing shareholders, including executives and private equity funds affiliated with Altus Capital Partners Inc.
The company, whose clients include Pfizer Inc and Exxon Mobil Corp, saw revenue rise 37.3 percent to $209.1 million in fiscal 2009, with net income of $5.5 million.
(Reporting by Phil Wahba, editing by Gerald E. McCormick, Tim Dobbyn, Leslie Gevirtz) Keywords: IPOS/DEBUTS (phil.wahba@thomsonreuters.com; +1 646 223 6128; Reuters Messaging: phil.wahba.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
